Join us at the 2015 BIO International Convention
We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our employees’ expertise and experience in R&D, manufacturing complex products and commercialization.
On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals.
Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.
For decades, we have solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all our stakeholders.
We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our
employees’ expertise and experience in R&D, manufacturing complex products and commercialization.
For more information on Adare, join us at the 2015 BIO International Convention for a capabilities presentation by Anthony Recupero, PhD, on June 16, 2015, at 4:15 PM in Theater 2, “The Gene Lantern.”
To learn more about our proprietary technologies or opportunities for product out-licensing, schedule a meeting through the BIO One-on-One Partnering™ System to meet with us at BIO International in Philadelphia, PA, June15-18, 2015.
If you are unable to attend BIO and would like to learn more about Adare, please contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com.
©2015 Adare Pharmaceuticals, Inc.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
